Sorghum Market is Anticipated To Generate Significant Revenues by 2030: Grand View Research Inc.

 Sorghum Market Growth & Trends

The global sorghum market size is expected to reach USD 31.77 billion by 2030, and expanding at a CAGR of 5.4% from 2024 to 2030 according to a new report by Grand View Research, Inc. Sorghum's gluten-free nature and rich nutritional values align with health-conscious consumer trends, fostering increased demand for sorghum-based products. Its versatility, finding applications in staple foods, livestock feed, ethanol production, and various industries, contributes to a broadening market. Business-to-business (B2B) dominance, climate resilience, continuous innovation in seed technology, government support, and its role in addressing food security needs further drive the expansion.

The increased demand for sorghum-based products is closely linked to the growing trend of health-conscious consumer behavior, particularly a surge in interest in gluten-free alternatives. Sorghum is a naturally gluten-free grain, making it a suitable choice for individuals who follow gluten-free diets due to celiac disease, or gluten sensitivity, or those who simply prefer to reduce gluten intake for health reasons. Sorghum offers several nutritional benefits that contribute to its popularity in the health-conscious market. It is a good source of essential nutrients such as fiber, protein, vitamins, and minerals. Additionally, sorghum has antioxidant properties, which are beneficial for overall health and well-being.

As consumers increasingly prioritize health and nutrition, there is an increased awareness of the potential drawbacks associated with gluten-containing grains for certain individuals. This has led to a surge in demand for alternative grains like sorghum, not only among those with specific dietary restrictions but also among a broader consumer base looking for diverse and nutritious food options. Food manufacturers and producers have responded to this trend by incorporating sorghum into a variety of products, ranging from gluten-free flour and baking mixes to cereals, snacks, and other processed foods. The versatility of sorghum in culinary applications has further fueled its adoption in the food industry, meeting the needs of consumers who seek both gluten-free options and nutritionally rich alternatives.

For instance, in March 2023, Mars, Inc.'s Seeds of Change brand launched a new Super Grains line, expanding its rice- and grain-based meal offerings. This includes the "Indian Style" flavor, featuring sorghum, quinoa, and finer millet. With the commitment to make ancient grains like sorghum more accessible and convenient, this initiative aligns with the broader trend of incorporating diverse and nutritious grains into mainstream diets.

Furthermore, advancements in seed technology have played a crucial role in enhancing the characteristics of sorghum varieties, leading to increased production. Ongoing research and development efforts in this field have focused on incorporating desirable traits into sorghum seeds, thereby addressing challenges and optimizing yields.

Request a free sample copy or view report summary: Sorghum Market Report

Sorghum Market Report Highlights

• In terms of revenue, grain sorghum dominated the market in 2023. Its versatility in culinary applications, including the production of porridges, flatbreads, and beverages, contributes to its prevalence in food consumption.
• Based on end use, the B2B segment dominated the market in 2023. The dominance isattributed to several factors, including heightened demand from diverse industries such as food and beverage, animal feed, ethanol production, and other industrial applications. The B2B sector's emphasis on bulk transactions, specialized product requirements, and long-term partnerships has driven the widespread adoption of sorghum for various applications, contributing to its dominance in the market.
• Middle East & Africa dominated the global market, driven by sorghum's status as a traditional staple, its adaptability to arid climates, and its crucial role in addressing food security challenges, supported by government initiatives and economic significance in the region.

Access Press Release@ https://www.grandviewresearch.com/press-release/sorghum-market-report

Sorghum Market Segmentation

Grand View Research has segmented the global sorghum market based on type, end-use, and region:

Sorghum Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Forage Sorghum
• Grain Sorghum
• Biomass Sorghum
• Sweet Sorghum

Sorghum End-use Outlook (Revenue in USD Billion, 2018 - 2030)

• B2B
  • Food & Beverages
  • Animal Feed
  • Ethanol Production
  • Others
• B2C

Sorghum Regional Outlook (Revenue, USD Billion, 2018 - 2030) 

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
• Central & South America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa

List of Key Players in the Sorghum Market

• Cargill, Incorporated
• ADM
• Seedway, LLC.
• Ernst Conservation Seeds
• The Scoular Company
• American Seed Co.
• Ardent Mills
• Advanta Seeds
• Nu Life Market
• Welter Seed & Honey Co

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Head And Neck Cancer Therapeutics Market To Hold a High Potential for Growth by 2030: Grand View Research Inc.

 Head And Neck Cancer Therapeutics Market Growth & Trends 

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030.  Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market. 

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide. 

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease. 

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA. 

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Request a free sample copy or view report summary: Head And Neck Cancer Therapeutics Market Report

Head And Neck Cancer Therapeutics Market Report Highlights 

• Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
• Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
• Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
• The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-head-neck-cancer-drugs-therapeutics-market

Head And Neck Cancer Therapeutics Market Segmentation

Grand View Research has segmented the global Head And Neck Cancer Therapeutics market on the basis of therapy type, route of administration, distribution channel, and region

Head And Neck Cancer Therapeutics Therapy Type Outlook (Revenue, USD Million, 2018 - 2030­)

• Chemotherapy
• Immunotherapy
• Targeted Therapy

Head And Neck Cancer Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Injectable
• Oral

Head And Neck Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail and Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Head And Neck Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

List of Key Players of Head And Neck Cancer Therapeutics Market

• Eli Lilly and Company
• Sanofi
• Merck & Co., Inc.
• Cumberland Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Hoffmann-La Roche Ltd.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Biopsy Guidance Systems Market Poised to Expand at a Robust Pace of $1.58 Billion Over 2030: Grand View Research Inc.

 Biopsy Guidance Systems Market Growth & Trends

The global biopsy guidance systems market size is expected to reach USD 1.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.1% from 2024 to 2030. The increasing prevalence of cancer, rise in the geriatric population, growing demand for non-invasive procedures, technological innovations, a rising number of government initiatives, and impact of COVID-19 are the key driving factors for the market.

A biopsy is one of the most prominent procedures for diagnosing cancer amongst other chronic diseases, and it is commonly employed in the diagnosis of breast, brain, skin, and prostate cancer. The increasing prevalence of cancer is a major factor responsible for market growth. For instance, according to Cancer.org, in 2021, around 1.9 million new cancer cases are expected to be diagnosed in the US. Since the biopsy guidance system is one of the major requirements for the initial diagnosis of cancer, thus, rising number of cancer cases is anticipated to propel market growth over the forecast period

Furthermore, there is a rising preference for minimally invasive biopsy treatments in the market. During the forecast period, several types of technologies and products including robot-assisted biopsy guidance systems, needle-based biopsy guns, and vacuum-assisted core biopsy systems, are expected to expand rapidly. For instance, in March 2021, IZI Medical Products, LLC launched Quick-Core Auto Biopsy System for soft tissue biopsy. It is a lightweight, completely automatic biopsy device and provides reliability, quality, and accuracy. Additionally, rising awareness of breast cancer treatment and diagnosis will further boost market growth over the forecast period.

Request a free sample copy or view report summary: Biopsy Guidance System Market Report

Biopsy Guidance Systems Market Report Highlights

• The stereotactic guided biopsy dominated the market and accounted for a share of 39.9% in 2023
• The brain biopsy section accounted for the largest market revenue share in 2023. Brain biopsy is considered the most reliable method to diagnose brain tumors that cannot be surgically removed.
• The healing centers segment dominated the industry and held the largest revenue share in 2023. It can be attributed to increased adoption of biopsy direction frameworks in clinics.
• North America biopsy guidance system market dominated the market and accounted for revenue share of 45.4% in 2023.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-biopsy-guidance-systems-market

Biopsy Guidance Systems Market Segmentation

Grand View Research has segmented the global Biopsy Guidance Systems market on the basis of product, application, end use, and region:

Biopsy Guidance System Product Outlook (Revenue, USD Million, 2018 - 2030)

• Stereotactic Guided Biopsy
• Ultrasound Guided Biopsy
• MRI Guided Biopsy

Biopsy Guidance System Application Outlook (Revenue, USD Million, 2018 - 2030)

• Brain Biopsy
• Breast Biopsy
• Other Applications

Biopsy Guidance System End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Research and Academic Institutes

Biopsy Guidance System Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in the Biopsy Guidance System Market

• Becton, Dickinson, and Company
• Hologic, Inc.
• Devicor Medical Products, Inc.
• Braun Melsungen AG
• ARGON MEDICAL
• Boston Scientific Corporation
• INRAD Inc.
• Cook Medical
• PLANMED OY

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Gene Therapy Market to Register Steadfast CAGR of 18.88% in Terms of Value from 2024 to 2030: Grand View Research Inc.

 

Gene Therapy Market Growth & Trends

The global gene therapy market is expected to reach USD 18.20 billion by 2030, registering a CAGR of 18.88% from 2024 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Request a free sample copy or view the report summary: Gene Therapy Market Report

Gene Therapy Market Report Highlights

• The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
• By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
• The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and β-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
• North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
• Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

Gene Therapy Market Segmentation

Grand View Research has segmented the global gene therapy market report based on indication, vector type, route of administration, and region:

Gene Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Large B-Cell Lymphoma
• Multiple Myeloma
• Spinal Muscular Atrophy (SMA)
• Acute Lymphoblastic Leukemia (ALL)
• Melanoma (lesions)
• Inherited Retinal Disease
• Beta-Thalassemia Major/SCD
• Others

Gene Therapy Vector Type Outlook (Revenue, USD Million, 2018 - 2030)

• Lentivirus
• RetroVirus & gamma RetroVirus
• AAV
• Modified Herpes Simplex Virus
• Adenovirus
• Others

Gene Therapy Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous
• Others

Gene Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • Switzerland
• Asia Pacific
  • Japan
  • China
  • South Korea
  • Australia
• Rest of the world 

List of Key Players in the Gene Therapy Market

• Amgen Inc.
• Novartis AG
• Hoffmann-La Roche
• Gilead Sciences, Inc.
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Legend Biotech.
• uniQure N.V.
• Merck & Co.
• Sarepta Therapeutics, Inc.
• Krystal Biotech, Inc.
• CRISPR Therapeutics

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Global Blister Packaging Market Pegged For Strong Growth During 2024-2030: Grand View Research Inc.

 Blister Packaging Market Growth & Trends

The global blister packaging market size is expected to reach USD 46.72 billion by 2030, expanding at 7.4% CAGR from 2024 to 2030, according to a new report by Grand View Research, Inc. This market growth is attributed to the increasing demand from healthcare end-use industries for tamper-evident packaging designs provided by blister packaging solutions and their high visibility properties.

This packaging solution is often used for tamper-evident packaging as it provides a sealed and visible container for products, allowing consumers to see if the product has been opened or tampered with. This type of packaging also makes it difficult to replace the product with counterfeit or other harmful substances without breaking the seal, providing an additional layer of protection for consumers.

Moreover, the demand for blister packaging is being driven by advancements in packaging design, including child-resistant packaging configurations, the emphasis on the use of recyclable materials, and the introduction of smart blister packaging solutions to provide information about the product and monitor its usage.

The industry players are adopting several strategies including partnerships, expansions, mergers & acquisitions, joint ventures, and partnership agreements to increase the customer base and individual market share. For instance, in January 2023, TekniPlex announced an expansion in its product portfolio by launching a highly visible and mid-barrier polypropylene (PE) blister packaging solution to cater to the healthcare end-use industry.

Request a free sample copy or view report summary: Blister Packaging Market Report

Blister Packaging Market Report Highlights

• A shift in consumer preference from traditional bottles for healthcare products to tamper-evident designed unit-dose blister packaging solutions and their cost-effective properties is driving the blister packaging industry
• The blister packaging made up of lightweight plastic films and paper is designed for smaller and lighter products. It cannot pack large and heavy products due to its limited strength and durability, which restrains market growth to a limited extent
• The plastic films segment is expected to grow at a fast CAGR during the forecast period of 2024 - 2030. This is attributed to plastic films such as polyethylene terephthalate (PET) and polyvinyl chloride (PVC) offering unique characteristics to the blister packaging solution such as high visibility, lighter weight, and low-cost properties
• The healthcare end-use segment recorded the highest market share in the base year 2023 due to the wide application of blister packaging in the packaging of generic drugs to protect them from external factors such as moisture and oxygen
• North America accounted for one of the largest market shares owing to the presence of several healthcare end-user industries such as Merck & Co., Inc.; Abbott; others, and an advanced healthcare system
• Several key companies are developing new products to strengthen their market positions in the blister packaging industry. For instance, in April 2023, SÜDPACK introducedmono-polypropylene blister packaging which is recyclable for the life science, medical goods, and pharmaceutical industries
• In January 2023, Amcor plc won the 2023 worldstar global packaging awards in four categories. Amcor received an award for its new HealthCare AmSky Blister System, an aluminum-free and PVC-free blister packaging of daily for dietary supplements and medications

Access Press Release@ https://www.grandviewresearch.com/press-release/global-blister-packaging-market

Blister Packaging Market Segmentation

Grand View Research has segmented the global blister packaging market based on material, technology, type, end-use, and region:

Blister Packaging Material Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)

• Paper & Paperboard
  • Solid Bleached Sulfate (SBS)
  • White-lined chipboard
  • Others
• Plastic Films
  • Polyvinyl Chloride (PVC)
  • Polyethylene Terephthalate (PET)
  • Polyethylene (PE)
  • Others
• Aluminum

Blister Packaging Technology Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)

• Thermoforming
• Cold Forming

Blister Packaging Type Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)

• Carded
• Clamshell

Blister Packaging End-use Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)

• Healthcare
• Consumer Goods
• Industrial Goods
• Food

Blister Packaging Regional Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
• Central & South America
  • Brazil
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa

List of Key Players in the Blister Packaging Market

• Amcor plc
• Dow
• WestRock Company
• Constantia Flexibles
• Honeywell International Inc.
• Sonoco Products Company
• Klockner Pentaplast
• TekniPlex
• UFlex Limited
• DuPont
• Display Pack
• WINPAK LTD.
• SteriPackGroup
• ACG
• SÜDPACK
• Blisterpack Inc.
• Abhinav Enterprises
• YuanPeng Plastic Technologys Co., Ltd
• Chadpak Co., Inc.
• Formpaks International Co. Ltd
• Uhlmann Group
• Wisser Verpackungen GmbH

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

UK Health Check-up Market Key Players ,Industry Share ,Growth, And Forecast To 2030: Grand View Research Inc.

 UK Health Check-up Market Growth & Trends

The UK health check-up market size is anticipated to reach USD 3.0 billion by 2030, growing at a CAGR of 6.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of chronic diseases and the need to provide preventive screening solutions. For instance, according to UK Health indicators, the top four most prevalent chronic conditions in the UK for both men and women are allergies, hypertension, lower back disorders, and depression. Allergies emerged as the most frequently reported chronic issue among both genders, with rates of 30.4% for men and 36.0% for women. Nearly half of the UK population, comprising 45.7% of men and 50.1% of women, disclosed experiencing a persistent condition. A higher proportion of women (22.3%) indicated experiencing some activity limitations due to health issues in the past six months compared to men (18.5%).

Rising government initiatives to provide healthcare solutions is further anticipated to drive market growth. For instance, in February 2024, the National Health Service (NHS) announce the launch of a digital version of the health check-up program for citizens in England. This initiative, known as the NHS Health Check, is designed for individuals aged 40 to 74, which translates to approximately 15 million people across the country. The check-up process typically involves an appointment with a general practitioner (GP), where patients are assessed for potential risks related to type 2 diabetes, strokes, kidney disease, and certain forms of dementia.

Moreover, the introduction of telemedicine in general healthcare practices has fueled the demand for home-based testing solutions. The healthcare ecosystem's digital connectivity framework has further empowered the market during the COVID-19 pandemic. The rising incidence of life-threatening diseases is a major driver for the market. This includes the growing prevalence of non-communicable diseases, such as diabetes, hypertension, cancer, and cardiovascular diseases. This combination of the increased availability of telemedicine and home-based testing, the escalating prevalence of life-threatening diseases, and the need for early detection of asymptomatic conditions are collectively expected to drive the growth and expansion of the market. These factors have enabled individuals to manage their health proactively and have contributed to the overall development of the healthcare ecosystem during the COVID-19 pandemic and beyond.

Furthermore, the rising strategic initiatives undertaken by the key players in the market, such as enhancing healthcare services and fostering collaborations between the public and private sectors, are expected to drive the overall development and expansion of the market. Additionally, the introduction of direct-to-customer testing solutions is anticipated to contribute to the growth and accessibility of check-up services during the forecast period. For instance, in June 2023, NHS announced the launch of home-based digital health checks. This new digital health check has been introduced with the aim of delivering an additional one million checks in the first four years.

Request a free sample copy or view report summary: UK Health Check-up Market Report

UK Health Check-up Market Report Highlights

• Blood, urine, body fluid tests segment dominated the test type segment and is anticipated to grow at the fastest growth rate over the forecast period owing to the rising adoption and usage of blood, urine, and body fluid samples in preventive care diagnosis.
• Individuals dominated the end-use segment; this is attributed to the growing awareness for preventive health among the population.
• Out-of-pocket dominated the individual end-use segment owing to the rising out-of-pocket spending expenditure by customers for personal check-ups.
• Enterprise segment held a significant share in end-use segment owing to the growing number of companies providing insurance to their employees.

Access Press Release@ https://www.grandviewresearch.com/press-release/uk-health-check-up-market-analysis

UK Health Check-up Market Segmentation

Grand View Research has segmented the UK health check-up market based on test type and end-use:

UK Health Check-up Test Type Category Outlook (Revenue, USD Million; 2018 - 2030)

• Blood, Urine, Body Fluid Tests
• Imaging-Based Tests (Xray, CT, US, MRI)
• Non-imaging Tests (ECG, CPET, NCS, EMG, EEG)

UK Health Check-up End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Enterprise
  • Private (Corporate) Sector
  • Government Sector
  • Insurance
• Individual
  • Out of Pocket- Direct Payment for Health Check
  • Individual Health Insurance Plan

List of Key Players in the UK Health Check-up Market

• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• SYNLAB International GmbH
• OPKO Health, Inc.
• Eurofins Scientific
• UNILABS
• Sonic Healthcare Limited
• ARUP Laboratories
• Q2 Solutions

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Data Monetization Solution For Healthcare Providers Market Trends, Company Share, Industry Growth And Future Scope

 Data Monetization Solution For Healthcare Providers Market Growth & Trends

The global data monetization solution for healthcare providers market size is expected to reach USD 293.1 million by 2030, registering a CAGR of 15.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness significant growth owing to the increasing demand for real-world evidence (RWE). Furthermore, rising healthcare databases and increasing need to reduce healthcare expenses are contributing to market growth. Additionally, increasing adoption of strategic initiatives by key market players is fostering market growth. For instance, in November 2022, Wipro Limited introduced the Wipro Data Intelligence Suite, an all-in-one answer for expediting cloud modernization and the monetization of data. The suite concentrates on the modernization of data estates, encompassing data stores, pipelines, and visualizations, operating on Amazon Web Services (AWS). These increasing product launches will escalate market growth.

The increasing usage of healthcare wearables and other digital health devices is fostering market growth. For instance, according to the June 2023 NIH report, nearly one in three Americans utilize a wearable device, like a smartwatch or band, to monitor their health and fitness. These devices generate vast amounts of real-time health data, including metrics such as heart rate, physical activity, sleep patterns, and other vital signs.When effectively aggregated and analyzed, this data can provide valuable insights into an individual's health status and behavior patterns. Therefore, by integrating data monetization solutions into their operations, providers can improve patient care and outcomes, as well as create new revenue streams.

Similarly, rising adoption of electronic health records (EHRs) across the globe is expected to boost market growth. For instance, in 2024, an article in Market.us Media reported that about 80% of primary care physicians in Germany utilize EHR systems. EHR usage in German hospitals stands at approximately 70%. The proportion of healthcare providers electronically sharing patient data is 53%.The monetization of electronic health record (EHR) data has the potential to create income and enhance patient care, treatment results, and the efficiency of the healthcare system.

The major players operating in the market are adopting strategies such as collaborations, supply agreements, and partnerships with a major focus on enhancing product formation and reach. For instance, in June 2021, Snowflake, the company known for its Data Cloud, revealed enhancements to its data offerings and capabilities on the Snowflake Data Marketplace. Furthermore, they announced the general availability of the Data Marketplace, aiming to assist customers from various industries in accessing a greater amount of data within the Data Cloud, thereby enabling them to gain more comprehensive data insights.

The increasing focus on patient-centered care and the growing demand for remote monitoring and telehealth are driving the need for data-driven insights in the healthcare sector. This is contributing to the growth of data monetization solutions. As healthcare systems worldwide move towards patient-centered models, there is a growing recognition of the importance of personalized care tailored to individual patient needs and preferences. This shift requires the collection and analysis of extensive health data to better understand patient populations and deliver targeted interventions, thereby fostering market growth.

Request a free sample copy or view report summary: Data Monetization Solution For Healthcare Providers Market Report

Data Monetization Solution For Healthcare Providers Market Report Highlights

• Based on type, the software segment held the largest revenue share in the market in 2023 owing to the growing demand for software solutions with advanced analytics and AI capabilities
• North America dominated the market due to the presence of key market players coupled with the region's robust healthcare infrastructure and advanced technological capabilities.
• In July 2022, Mayo Clinic and Mercy entered into a 10-year collaboration agreement, marking the first-ever alliance between two major health care systems. This partnership leveraged the latest data science and extensive de-identified patient outcomes to detect diseases at an earlier stage and expedite patients' journey to improved health

Access Press Release@ https://www.grandviewresearch.com/press-release/global-data-monetization-solution-healthcare-providers-market

Data Monetization Solution For Healthcare Providers Market Segmentation

Grand View Research has segmented the data monetization solution for healthcare providers market based on type and region:

Data Monetization Solution For Healthcare Providers Type Outlook (Revenue, USD Million, 2018 - 2030)

• Software
• Services

Data Monetization Solution For Healthcare Providers Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in the Data Monetization Solution For Healthcare Providers Market:

• Microsoft Corporation
• Oracle Corporation
• SAP SE
• SAS Institute Inc.
• Salesforce, Inc
• Snowflake Inc.
• Siemens
• TIBCO Software Inc.
• Virtusa Corp.
• H1

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Logistics Automation Market Is Expected To Accomplish A Valuation Of Around USD 90.0 Billion By 2030: Grand View Research Inc.

Logistics Automation Market Growth & Trends

The global logistics automation market size is anticipated to reach USD 90.0 billion by 2030, expanding at a CAGR of 15.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Logistics operations are critical factors in the smooth functioning of the supply chain of any business, especially low-margin, high-volume businesses. The logistics sector is witnessing a continuous increase in investments with a significant emphasis on the automation of several logistics functions. Automation enhances efficiency and aids in integrating supply chains; thus, automation is increasingly being adopted across sectors. The growing tendency of the logistics industry toward adopting automation solutions is one of the significant factors driving the growth of the logistics automation industry.

According to a DHL report published in 2018, 80% of warehouses do not have any automation support and are still operated manually, while 15% of the total warehouses are just mechanized, which means the warehouses use sorters, conveyors, picker solutions, and other machined equipment which are not necessarily automated. The report states that only 5% of total warehouses are automated. The trend displays a remarkable opportunity for the growth of the market in the coming years as companies are increasingly adopting automation in their warehouses, including autonomous robots, automated sorting systems, conveyor systems, etc. Technological developments such as communication technologies, sensors, tracking devices, computer vision, artificial intelligence, and machine learning are aiding the growth of the target market.

The e-commerce boom is resulting in increasing adoption of automation solutions owing to the enormous volumes of shipments. The e-commerce shipment volume is growing exponentially by the year, and hence the warehouses require automation solutions to meet the short delivery timelines. The e-commerce fulfillment centers are implementing automated sorting and conveyor systems and highly benefit from inventory management and order management software. Moreover, the major labor challenges faced by the logistics industry across the globe are driving the demand for logistics automation solutions.

Request a free sample copy or view report summary: Logistics Automation Market Report

Logistics Automation Market Report Highlights

• Based on components, the hardware segment dominated the market in 2023 with a share of about 66%. Autonomous robots are the largest sub-segment of hardware components in terms of revenue owing to the increasing demand for automated warehouse logistics
• Based on function, the inventory & storage management function segment is anticipated to grow at a CAGR of 16.2% during the forecast period. The inventory & storage management ensures the stocks are maintained at optimum levels, and the demand for each product determines the stock levels
• Based on logistics type, the sales logistics segment dominated the market in 2023, accounting for a market share of about 35%. Sales logistics is a critical aspect of the supply chain as it involves moving or delivering goods to the end consumer
• Based on organization size, the small and medium enterprises segment is anticipated to grow at the fastest CAGR of 16.0% during the forecast period. The growth can be attributed to the automation that helps SMEs to optimize their labor costs
• Based on software application, the order management software segment held the largest market share in 2023. The dominance of the segment is owing to the need to fulfill the orders correctly and without any delivery delays. The order management process starts when an order is placed and ends when the customer receives the order
• Based on vertical, the retail and e-commerce segment is anticipated to grow at a CAGR of 15.6%. The growth can be attributed to the increasing preference for online shopping among consumers across the globe
• The Asia Pacific segment is anticipated to register significant growth with a CAGR of 15.5%. The growth can be attributed to the increasing investments in logistics infrastructure projects in countries such as India and China
• In March 2023, Jungheinrich AG announced the acquisition of Storage Solutions, a material handling solution provider based in the U.S. Storage Solutions provides warehouse and distribution centers with solutions and services, such as lifecycle services, workflow optimization, and safety inspections. Jungheinrich AG was looking forward to leveraging the acquisition to expand its presence in the U.S.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-logistics-automation-market

Logistics Automation Market Segmentation

Grand View Research has segmented the global logistics automation market based on component, function, logistics type, organization size, software application, vertical, and region:

Logistics Automation Component Outlook (Revenue, USD Million, 2017 - 2030)

• Hardware
  • Autonomous Robots (AGV, AMR)
  • Automated Storage and Retrieval Systems (AS/RS)
  • Automated Sorting Systems
  • De-palletizing/Palletizing Systems
  • Conveyor Systems
  • Automatic Identification and Data Collection (AIDC)
• Software
  • Warehouse Management System
  • Transportation Management System
• Services
  • Consulting
  • Deployment & Integration
  • Support & Maintenance

Logistics Automation Function Outlook (Revenue, USD Million, 2017 - 2030)

• Inventory & Storage Management
• Transportation Management

Logistics Automation Logistics Type Outlook (Revenue, USD Million, 2017 - 2030)

• Sales Logistics
• Production Logistics
• Recovery Logistics
• Procurement Logistics

Logistics Automation Organization Size Outlook (Revenue, USD Million, 2017 - 2030)

• Large Enterprises
• Small & Medium Enterprises

Logistics Automation Software Application Outlook (Revenue, USD Million, 2017 - 2030)

• Inventory Management
• Order Management
• Yard Management
• Shipping Management
• Labor Management
• Vendor Management
• Customer Support
• Others

Logistics Automation Vertical Outlook (Revenue, USD Million, 2017 - 2030)

• Retail & E-commerce
• Healthcare
• Automotive
• Aerospace & Defense
• Electronics & Semiconductors
• Others

Logistics Automation Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• Latin America
  • Brazil
• Middle East & Africa
  • KSA
  • UAE
  • South Africa

List of Key Players in the Logistics Automation Market

• Dematic (Kion Group AG)
• Daifuku Co., Ltd.
• Swisslog Holding AG (KUKA AG)
• Honeywell International Inc.
• Murata Machinery, Ltd.
• Jungheinrich AG
• KNAPP AG
• TGW Logistics Group
• Kardex
• Mecalux, S.A.
• BEUMER GROUP
• SSI SCHÄFER AG
• Vanderlande Industries B.V.
• WITRON Logistik
• Oracle
• One Network Enterprises
• SAP

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Expansion of Intravenous Iron Drugs Market During 2024 – 2030 to Gain Robust Traction: Grand View Research Inc.

 Intravenous Iron Drugs Market Growth & Trends

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Request a free sample copy or view report summary: Intravenous Iron Drugs Market Report

Intravenous Iron Drugs Market Report Highlights

• Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost
• Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs
• The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases
• North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD
• Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players
• Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Access Press Release@ https://www.grandviewresearch.com/press-release/global-intravenous-iron-drugs-market

Intravenous Iron Drugs Market Segmentation

Grand View Research has segmented the global intravenous iron drugs market based on product, application,and region:

Intravenous Iron Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others

Intravenous Iron Drugs Application Outlook (Revenue, USD Million, 2018 - 2030)

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Diseases

Intravenous Iron Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in Intravenous Iron Drugs Market

• AbbVie Inc.
• AMAG Pharmaceuticals (Covis Pharma)
• Daiichi Sankyo Company, Ltd.
• Sanofi
• Vifor Pharma Management Ltd. (CSL)
• PHARMACOSMOS A/S
• Zydus Group
• Rockwell Medical, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Migraine Drugs Market Estimated to Experience a Hike in Growth by 2030|Top Industry Players Pfizer, GlaxoSmithKline

 

Migraine Drugs Market Growth & Trends

The global migraine drugs market size is expected to be valued at USD 13.34 billion by 2030, as per a new report by Grand View Research, Inc., exhibiting an 11.9% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Request a free sample copy or view report summary: Migraine Drugs Market Report

Migraine Drugs Market Report Highlights

• Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
• The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
• Biohaven’s rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
• Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
• Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
• Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (a combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-migraine-drugs-market

Migraine Drugs Market Segmentation

Grand View Research has segmented the global migraine drugs market based on treatment, therapeutic class, route of administration, age group, availability, and region:

Migraine Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Acute
• Preventive

Migraine Drugs Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)

• CGRP monoclonal antibodies
• CGRP small molecule antagonists
• Acetylcholine inhibitors/ neurotoxins
• Triptans
• Ditans
• Ergot alkaloids
• NSAIDs
• Others

Migraine Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Injectable
• Others

Migraine Drugs Age Group Outlook (Revenue, USD Million, 2018 - 2030)

• Pediatric
• Adult
• Geriatric

Migraine Drugs Availability Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

Migraine Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

List of Key Players in the Migraine Drugs Market

• AbbVie Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• Eli Lilly and Company
• Pfizer Inc.
• Bausch Health Companies Inc.
• Gensco Pharma
• Impel Pharmaceuticals Inc.
• Tonix Medicines, Inc.
• Currax Pharmaceuticals LLC.
• Lundbeck

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.